Sung-Yun Pai

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2470628/publications.pdf

Version: 2024-02-01

124 papers	9,394 citations	46918 47 h-index	39575 94 g-index
133 all docs	133 docs citations	133 times ranked	10472 citing authors

#	Article	IF	Citations
1	Transplantation Outcomes for Severe Combined Immunodeficiency, 2000â€“2009. New England Journal of Medicine, 2014, 371, 434-446.	13.9	594
2	Newborn Screening for Severe Combined Immunodeficiency in 11 Screening Programs in the United States. JAMA - Journal of the American Medical Association, 2014, 312, 729.	3.8	586
3	Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood, 2013, 121, 5113-5123.	0.6	507
4	A Modified Î³-Retrovirus Vector for X-Linked Severe Combined Immunodeficiency. New England Journal of Medicine, 2014, 371, 1407-1417.	13.9	358
5	GATA3 and the T-cell lineage: essential functions before and after T-helper-2-cell differentiation. Nature Reviews Immunology, 2009, 9, 125-135.	10.6	344
6	GATA-3 Links Tumor Differentiation and Dissemination in a Luminal Breast Cancer Model. Cancer Cell, 2008, 13, 141-152.	7.7	314
7	Establishing diagnostic criteria for severe combined immunodeficiency disease (SCID), leaky SCID, and Omenn syndrome: The Primary Immune Deficiency Treatment Consortium experience. Journal of Allergy and Clinical Immunology, 2014, 133, 1092-1098.	1.5	301
8	GATA-3 deficiency abrogates the development and maintenance of T helper type 2 cells. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 1993-1998.	3.3	299
9	Long-term outcome and lineage-specific chimerism in 194 patients with Wiskott-Aldrich syndrome treated by hematopoietic cell transplantation in the period 1980-2009: an international collaborative study. Blood, 2011, 118, 1675-1684.	0.6	296
10	DOCK8 Deficiency: Clinical and Immunological Phenotype and Treatment Options - a Review of 136 Patients. Journal of Clinical Immunology, 2015, 35, 189-198.	2.0	284
11	Critical Roles for Transcription Factor GATA-3 in Thymocyte Development. Immunity, 2003, 19, 863-875.	6.6	277
12	Post-Transcriptional Genetic Silencing ofBCL11Ato Treat Sickle Cell Disease. New England Journal of Medicine, 2021, 384, 205-215.	13.9	250
13	Human HOIP and LUBAC deficiency underlies autoinflammation, immunodeficiency, amylopectinosis, and lymphangiectasia. Journal of Experimental Medicine, 2015, 212, 939-951.	4.2	241
14	Long-term follow-up of IPEX syndrome patients after different therapeutic strategies: An international multicenter retrospective study. Journal of Allergy and Clinical Immunology, 2018, 141, 1036-1049.e5.	1.5	233
15	Immune reconstitution and survival of 100 SCID patients postâ€“hematopoietic cell transplant: a PIDTC natural history study. Blood, 2017, 130, 2718-2727.	0.6	212
16	Lentiviral gene therapy for X-linked chronic granulomatous disease. Nature Medicine, 2020, 26, 200-206.	15.2	175
17	The syndrome of hemophagocytic lymphohistiocytosis in primary immunodeficiencies: implications for differential diagnosis and pathogenesis. Haematologica, 2015, 100, 978-988.	1.7	161
18	Small-molecule screen identifies reactive oxygen species as key regulators of neutrophil chemotaxis. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 3546-3551.	3.3	141

#	Article	IF	Citations
19	Whole-exome sequencing identifies tetratricopeptide repeat domain 7A (TTC7A) mutations for combined immunodeficiency with intestinal atresias. Journal of Allergy and Clinical Immunology, 2013, 132, 656-664.e17.	1.5	140
20	IL-21 is the primary common Î³ chain-binding cytokine required for human B-cell differentiation in vivo. Blood, 2011, 118, 6824-6835.	0.6	132
21	A systematic analysis of recombination activity andÂgenotype-phenotype correlation in human recombination-activating gene 1 deficiency. Journal of Allergy and Clinical Immunology, 2014, 133, 1099-1108.e12.	1.5	132
22	SCID genotype and 6-month posttransplant CD4 count predict survival and immune recovery. Blood, 2018, 132, 1737-1749.	0.6	128
23	GATA-3 Regulates the Development and Function of Invariant NKT Cells. Journal of Immunology, 2006, 177, 6650-6659.	0.4	108
24	The Natural History of Children with Severe Combined Immunodeficiency: Baseline Features of the First Fifty Patients of the Primary Immune Deficiency Treatment Consortium Prospective Study 6901. Journal of Clinical Immunology, 2013, 33, 1156-1164.	2.0	100
25	Very Early Onset Inflammatory Bowel Disease: A Clinical Approach With a Focus on the Role of Genetics and Underlying Immune Deficiencies. Inflammatory Bowel Diseases, 2020, 26, 820-842.	0.9	100
26	A Markov model to analyze cost-effectiveness of screening for severe combined immunodeficiency (SCID). Molecular Genetics and Metabolism, 2011, 104, 383-389.	0.5	93
27	Characterization of T and B cell repertoire diversity in patients with RAG deficiency. Science Immunology, 2016, 1, .	5.6	88
28	Excellent outcomes following hematopoietic cell transplantation for Wiskott-Aldrich syndrome: a PIDTC report. Blood, 2020, 135, 2094-2105.	0.6	87
29	CDK Inhibitor p18INK4c Is a Downstream Target of GATA3 and Restrains Mammary Luminal Progenitor Cell Proliferation and Tumorigenesis. Cancer Cell, 2009, 15, 389-401.	7.7	82
30	Comparison of outcomes of hematopoietic stem cell transplantation without chemotherapy conditioning by using matched sibling and unrelated donors for treatment ofÂsevere combined immunodeficiency. Journal of Allergy and Clinical Immunology, 2014, 134, 935-943.e15.	1.5	82
31	Universal Newborn Screening for Severe Combined Immunodeficiency (SCID). Frontiers in Pediatrics, 2019, 7, 373.	0.9	82
32	Lipid defect underlies selective skin barrier impairment of an epidermal-specific deletion of Gata-3. Journal of Cell Biology, 2006, 175, 661-670.	2.3	80
33	Reduced-intensity conditioning for hematopoietic cell transplant for HLH and primary immune deficiencies. Blood, 2018, 132, 1438-1451.	0.6	78
34	High-Throughput Multiplexed T-Cellâ€“Receptor Excision Circle Quantitative PCR Assay with Internal Controls for Detection of Severe Combined Immunodeficiency in Population-Based Newborn Screening. Clinical Chemistry, 2010, 56, 1466-1474.	1.5	74
35	Rac GTPases in Human Diseases. Disease Markers, 2010, 29, 177-187.	0.6	71
36	GATA-3 - not just for Th2 cells anymore. Cellular and Molecular Immunology, 2007, 4, 15-29.	4.8	71

#	Article	IF	Citations
37	Effect of Weight and Maturation on Busulfan Clearance in Infants and Small Children Undergoing Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2013, 19, 1608-1614.	2.0	69
38	Hematopoietic Stem Cell Transplantation as Treatment for Patients with DOCK8 Deficiency. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 848-855.	2.0	67
39	Primary Immune Deficiency Treatment Consortium (PIDTC) report. Journal of Allergy and Clinical Immunology, 2014, 133, 335-347.e11.	1.5	65
40	Outcomes and Treatment Strategies for Autoimmunity and Hyperinflammation in Patients with RAG Deficiency. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 1970-1985.e4.	2.0	64
41	The genetic landscape of severe combined immunodeficiency in the United States and Canada in the current era (2010-2018). Journal of Allergy and Clinical Immunology, 2019, 143, 405-407.	1.5	64
42	Flow cytometry diagnosis of dedicator of cytokinesis 8 (DOCK8) deficiency. Journal of Allergy and Clinical Immunology, 2014, 134, 221-223.e7.	1.5	62
43	Successful engraftment of donor marrow after allogeneic hematopoietic cell transplantation in autosomal-recessive hyper-IgE syndrome caused by dedicator of cytokinesis 8 deficiency. Journal of Allergy and Clinical Immunology, 2010, 126, 1304-1305.e3.	1.5	61
44	Guidelines for implementation of populationâ€based newborn screening for severe combined immunodeficiency. Journal of Inherited Metabolic Disease, 2010, 33, 273-281.	1.7	60
45	Expanding the spectrum of recombination-activating gene 1 deficiency: AÂfamily with early-onset autoimmunity. Journal of Allergy and Clinical Immunology, 2013, 132, 969-971.e2.	1.5	59
46	Hematopoietic Cell Transplantation in Patients With Primary Immune Regulatory Disorders (PIRD): A Primary Immune Deficiency Treatment Consortium (PIDTC) Survey. Frontiers in Immunology, 2020, 11, 239.	2.2	57
47	Patients with CD3G mutations reveal a role for human CD3Î³ in Treg diversity and suppressive function. Blood, 2018, 131, 2335-2344.	0.6	51
48	Hematopoietic Cell Transplantation for Wiskott-Aldrich Syndrome: Advances in Biology and Future Directions for Treatment. Immunology and Allergy Clinics of North America, 2010, 30, 179-194.	0.7	50
49	A novel mutation in the POLE2 geneÂcausing combined immunodeficiency. Journal of Allergy and Clinical Immunology, 2016, 137, 635-638.e1.	1.5	49
50	Allogeneic hematopoietic stem cell transplantation for X-linked ectodermal dysplasia and immunodeficiency: case report and review of outcomes. Immunologic Research, 2009, 44, 89-98.	1.3	48
51	Identification of an infant with severe combined immunodeficiency by newborn screening. Journal of Allergy and Clinical Immunology, 2010, 126, 1073-1074.	1.5	48
52	Hematopoietic stem cell transplantation outcomes for 11 patients with dedicator of cytokinesis 8 deficiency. Journal of Allergy and Clinical Immunology, 2016, 138, 852-859.e3.	1.5	48
53	Allogeneic transplantation successfully corrects immune defects, but not susceptibility to colitis, in a patient with nuclear factor-ÎºB essential modulator deficiency. Journal of Allergy and Clinical Immunology, 2008, 122, 1113-1118.e1.	1.5	45
54	Natural Killer Cells from Patients with Recombinase-Activating Gene and Non-Homologous End Joining Gene Defects Comprise a Higher Frequency of CD56bright NKG2A+++ Cells, and Yet Display Increased Degranulation and Higher Perforin Content. Frontiers in Immunology, 2017, 8, 798.	2.2	41

#	Article	IF	Citations
55	Chronic Granulomatous Disease-Associated IBD Resolves and Does Not Adversely Impact Survival Following Allogeneic HCT. Journal of Clinical Immunology, 2019, 39, 653-667.	2.0	41
56	Next Generation Sequencing Reveals Skewing of the T and B Cell Receptor Repertoires in Patients with WiskottÃ¢â‚¬â€œAldrich Syndrome. Frontiers in Immunology, 2014, 5, 340.	2.2	40
57	Stem cell transplantation for tetratricopeptide repeat domain 7A deficiency: long-term follow-up. Blood, 2016, 128, 1306-1308.	0.6	40
58	WASP-mediated regulation of anti-inflammatory macrophages is IL-10 dependent and is critical for intestinal homeostasis. Nature Communications, 2018, 9, 1779.	5.8	40
59	GATA-3 Regulates the Homeostasis and Activation of CD8+ T Cells. Journal of Immunology, 2013, 190, 428-437.	0.4	37
60	B-cell differentiation and IL-21 response in IL2RG/JAK3 SCID patients after hematopoietic stem cell transplantation. Blood, 2018, 131, 2967-2977.	0.6	37
61	Reduced thymic output, cell cycle abnormalities, and increased apoptosis of T lymphocytes in patients with cartilage-hair hypoplasia. Journal of Allergy and Clinical Immunology, 2011, 128, 139-146.	1.5	36
62	Stem cell transplantation for primary immunodeficiency diseases. Current Opinion in Allergy and Clinical Immunology, 2014, 14, 521-526.	1.1	36
63	Infections in Infants with SCID: Isolation, Infection Screening, and Prophylaxis in PIDTC Centers. Journal of Clinical Immunology, 2021, 41, 38-50.	2.0	36
64	The current status of treatment for anorexia nervosa and bulimia nervosa. International Journal of Eating Disorders, 1992, 12, 215-220.	2.1	34
65	Cross-linking CD28 leads to activation of 70-kDa S6 kinase. European Journal of Immunology, 1994, 24, 2364-2368.	1.6	34
66	Fatal autoimmunity in mice reconstituted with human hematopoietic stem cells encoding defective FOXP3. Blood, 2015, 125, 3886-3895.	0.6	33
67	Rac GTPases in human diseases. Disease Markers, 2010, 29, 177-87.	0.6	33
68	First reported case of Omenn syndrome in a patient with reticular dysgenesis. Journal of Allergy and Clinical Immunology, 2013, 131, 1227-1230.e3.	1.5	32
69	Pharmacokinetics and Model-Based Dosing to Optimize Fludarabine Therapy in Pediatric Hematopoietic Cell Transplant Recipients. Biology of Blood and Marrow Transplantation, 2017, 23, 1701-1713.	2.0	32
70	Reticular dysgenesis: international survey on clinical presentation, transplantation, and outcome. Blood, 2017, 129, 2928-2938.	0.6	31
71	p53⁺/mdm2^{â˜} Atypical Lipomatous Tumor/Well-Differentiated Liposarcoma in Young Children: An Early Expression of Li-Fraumeni Syndrome. Pediatric and Developmental Pathology, 2010, 13, 218-224.	0.5	28
72	A novel mutation in ORAI1 presenting with combined immunodeficiency and residual T-cell function. Journal of Allergy and Clinical Immunology, 2015, 136, 479-482.e1.	1.5	28

#	Article	IF	Citations
73	T cell dynamics and response of the microbiota after gene therapy to treat X-linked severe combined immunodeficiency. Genome Medicine, 2018, 10, 70.	3.6	28
74	Disrupted N-linked glycosylation as a disease mechanism in deficiency of ADA2. Journal of Allergy and Clinical Immunology, 2018, 142, 1363-1365.e8.	1.5	28
75	Diagnostic assay to assist clinical decisions for unclassified severe combined immune deficiency. Blood Advances, 2020, 4, 2606-2610.	2.5	28
76	Hypomorphic Janus kinase 3 mutations result in a spectrum of immune defects, including partial maternal T-cell engraftment. Journal of Allergy and Clinical Immunology, 2013, 131, 1136-1145.	1.5	27
77	A novel mutation in ICOS presenting as hypogammaglobulinemia with susceptibility to opportunistic pathogens. Journal of Allergy and Clinical Immunology, 2015, 136, 794-797.e1.	1.5	26
78	Itm2a, a Target Gene of GATA-3, Plays a Minimal Role in Regulating the Development and Function of T Cells. PLoS ONE, 2014, 9, e96535.	1.1	26
79	Broad spectrum of autoantibodies in patients with Wiskott-Aldrich syndrome and X-linked thrombocytopenia. Journal of Allergy and Clinical Immunology, 2015, 136, 1401-1404.e3.	1.5	25
80	Gene Therapy Through Autologous Transplantation of Gene-Modified Hematopoietic Stem Cells. Biology of Blood and Marrow Transplantation, 2013, 19, S64-S69.	2.0	23
81	Treatment of primary immunodeficiency with allogeneic transplant and gene therapy. Hematology American Society of Hematology Education Program, 2019, 2019, 457-465.	0.9	22
82	Ten Years of Newborn Screening for Severe Combined Immunodeficiency (SCID) in Massachusetts. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 2060-2067.e2.	2.0	20
83	Defining a new immune deficiency syndrome: MAN2B2-CDG. Journal of Allergy and Clinical Immunology, 2020, 145, 1008-1011.	1.5	19
84	Gene therapy for X-linked severe combined immunodeficiency: Historical outcomes and current status. Journal of Allergy and Clinical Immunology, 2020, 146, 258-261.	1.5	19
85	Outcome of Hematopoietic Stem Cell Gene Therapy for Wiskott-Aldrich Syndrome. Blood, 2019, 134, 4629-4629.	0.6	17
86	Autoimmune lymphoproliferative syndrome caused by a homozygous FasL mutation that disrupts FasL assembly. Journal of Allergy and Clinical Immunology, 2016, 137, 324-327.e2.	1.5	13
87	T-cell mitochondrial dysfunction and lymphopenia in DOCK2-deficient patients. Journal of Allergy and Clinical Immunology, 2019, 144, 306-309.e2.	1.5	13
88	Gene Therapy Using a Self-Inactivating Lentiviral Vector Improves Clinical and Laboratory Manifestations of Wiskott-Aldrich Syndrome. Blood, 2015, 126, 260-260.	0.6	12
89	Distinct Structural Requirements of GATA-3 for the Regulation of Thymocyte and Th2 Cell Differentiation. Journal of Immunology, 2008, 180, 1050-1059.	0.4	11
90	Novel presentation of Omenn syndrome in association with aniridia. Journal of Allergy and Clinical Immunology, 2009, 123, 966-969.	1.5	10

#	Article	IF	Citations
91	Vasculitis as a Major Morbidity Factor in Patients With Partial RAG Deficiency. Frontiers in Immunology, 2020, 11, 574738.	2.2	10
92	c-Rel delivers a one-two punch in Th1 cell differentiation. Journal of Clinical Investigation, 2002, 110, 741-742.	3.9	8
93	A Curative DNA Code for Hematopoietic Defects. Hematology/Oncology Clinics of North America, 2022, 36, 647-665.	0.9	6
94	Most Closely HLA-Matched Allogeneic Virus Specific Cytotoxic T-Lymphocytes (CTL) to Treat Persistent Reactivation or Infection With Adenovirus, CMV and EBV After Hemopoietic Stem Cell Transplantation (HSCT). Biology of Blood and Marrow Transplantation, 2011, 17, S151-S152.	2.0	4
95	Genotype, Phenotype and T Cell Counts at One Year Predict Survival and Long Term Immune Reconstitution after Transplantation in Severe Combined Immune Deficiency (SCID)â€"The Primary Immune Deficiency Treatment Consortium (PIDTC). Biology of Blood and Marrow Transplantation, 2017, 23, S133-S134.	2.0	4
96	Hematopoietic Stem Cell Transplantation Is a Curative Therapy for Transferrin Receptor 1 (TFRC) Deficiency. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 753-759.e2.	2.0	4
97	Poor T Cell Reconstitution at 100 Days after T Cell-Replete Hematopoietic Cell Transplantation (HCT) for SCID Is Associated with Later Risk of Death or Need for 2nd Transplant in the 6901 Prospective Study of the Pidtc. Biology of Blood and Marrow Transplantation, 2016, 22, S101-S102.	2.0	3
98	Transplantation Outcomes for Children with Severe Combined Immune Deficiency (SCID) Have Improved over Time: A 36-Year Summary Report By the Primary Immune Deficiency Treatment Consortium (PIDTC). Biology of Blood and Marrow Transplantation, 2020, 26, S18-S19.	2.0	3
99	Somatic Gene Therapy for X-Linked Severe Combined Immunodeficiency Using a Self-Inactivating Modified Gammaretroviral Vector Results in An Improved Preclinical Safety Profile and Early Clinical Efficacy in a Human Patient. Blood, 2011, 118, 164-164.	0.6	3
100	c-Rel delivers a one-two punch in Th1 cell differentiation. Journal of Clinical Investigation, 2002, 110, 741-742.	3.9	3
101	363 Human Hematopoietic Stem Cells With a Defined Immunodeficiency and Enteropathy Transfer Clinical Phenotype to a Novel Humanized Mouse Strain. Gastroenterology, 2014, 146, S-81.	0.6	2
102	Early Hematopoietic Cell Transplant (HCT) Outcomes of Children with Severe Combined Immunodeficiency Disease (SCID): The First Seventy Four Patients of the Primary Immune Deficiency Treatment Consortium (PIDTC) Prospective Study 6901. Biology of Blood and Marrow Transplantation, 2015, 21, S289-S291.	2.0	2
103	HSCT for DOCK8 Deficiency - an International Study on 74 Patients. Biology of Blood and Marrow Transplantation, 2016, 22, S103-S104.	2.0	2
104	Resolution of CGD Related Colitis after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Chronic Granulomatous Diseaseâ€"Early Results From the 6903 Study of the Primary Immune Deficiency Treatment Consortium (PIDTC). Biology of Blood and Marrow Transplantation, 2018, 24, S80-S81.	2.0	2
105	Congenital Disorders of Lymphocyte Function. , 2018, , 710-723.e3.		2
106	Vasculitis as a major morbidity factor in patients with hypomorphic RAG mutations. Journal of Allergy and Clinical Immunology, 2019, 143, AB116.	1.5	2
107	Novel Compound Heterozygous Mutations in ZAP70 Leading to a SCID Phenotype with Normal Downstream In vitro Signaling. Journal of Clinical Immunology, 2021, 41, 470-472.	2.0	2
108	Multicenter Study of â€œoff-the-Shelfâ€•Third Party Virus-Specific T Cells (VSTs) to Treat Adenovirus (Adv), Cytomegalovirus (CMV) or Epstein Barr Virus (EBV) Infection After Hemopoietic Stem Cell Transplantation (HSCT). Blood, 2012, 120, 457-457.	0.6	2

#	Article	IF	Citations
109	Intestinal atresias and intestinal failure in patients with TTC7A mutations. Journal of Pediatric Surgery Case Reports, 2022, 80, 102247.	0.1	2
110	Retrospective Study of 240 Patients with Severe Combined Immunodeficiency Transplanted from 2000-2009: A Report from the Primary Immune Deficiency Treatment Consortium of North America. Biology of Blood and Marrow Transplantation, 2014, 20, S24-S25.	2.0	1
111	A Case of Leaky SCID with Variable Presentation in Two Siblings Identified By Newborn Screening. Journal of Allergy and Clinical Immunology, 2015, 135, AB15.	1.5	1
112	O-008â€ƒAberrant Anti-inflammatory Macrophage Function and Differentiation in Wiskott-Aldrich Syndrome Protein-Deficient Mice and Humans. Inflammatory Bowel Diseases, 2016, 22, S3.	0.9	1
113	Getting Past HSC Security: Cyclosporine H Gives Lentiviruses an Entry Pass. Cell Stem Cell, 2018, 23, 775-776.	5.2	1
114	Third-Party Virus-Specific T-Cell Infusion for Treatment of Refractory Viral Infections: Interim Results from PBMTC SUP1701. Biology of Blood and Marrow Transplantation, 2020, 26, S89-S90.	2.0	1
115	Pulmonary Complications in Patients with Primary Immunodeficiency Undergoing Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2020, 26, S16-S17.	2.0	1
116	Preclinical Development of Gene Therapy for X-Linked Severe Combined Immunodeficiency (SCID-X1). Blood, 2016, 128, 4705-4705.	0.6	1
117	Characteristics and outcomes of autoimmune hemolytic anemia after pediatric allogeneic stem cell transplant. Pediatric Blood and Cancer, 2022, 69, e29410.	0.8	1
118	P-200â€ƒHuman Hematopoietic Stem Cells with a Defined Immunodeficiency Transfer Clinical Phenotype to Novel Humanized Mouse Strain. Inflammatory Bowel Diseases, 2013, 19, S105.	0.9	0
119	Plasma and Intracellular Pharmacokinetic (PK) Analysis of Fludarabine in Pediatric Allogeneic Hematopoietic Cell Transplant (alloHCT) Recipients. Biology of Blood and Marrow Transplantation, 2016, 22, S253.	2.0	0
120	Long-Term Treatment Outcome in IPEX Syndrome Patients: An International Multicenter Retrospective Study. Biology of Blood and Marrow Transplantation, 2018, 24, S86-S87.	2.0	0
121	174.â€ƒVASCULITIS AS A MAJOR MORBIDITY FACTOR IN PATIENTS WITH HYPOMORPHIC RAG VARIANTS. Rheumatology, 2019, 58, .	0.9	0
122	Immune Reconstitution Therapy for Immunodeficiency. , 2019, , 1115-1128.e1.		0
123	Stem cell transplantation and immune reconstitution in immunodeficiency. , 2013, , 1007-1019.		0
124	Inducible Phase Separation of GSK3Î± As a Mechanism for Asparaginase Resistance in Acute Leukemias. Blood, 2019, 134, 169-169.	0.6	0